Monte Rosa Therapeutics, Inc
Scientist, Analytical CMC & QC with Analytical expertise to support analytical activities related to the development and supply of drug substance and drug product for molecular glue degrader (MGD) programs.
Monte Rosa Therapeutics is a biotechnology company pioneering molecular glue degrader (MGD) therapies that promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, traditionally undruggable proteins. Their drug discovery platform integrates expertise in MGD chemistry, artificial intelligence, structural biology, and proteomics to rapidly advance programs targeting undruggable or inadequately drugged targets with unprecedented specificity. Focused on cancer and beyond, the company operates out of Boston, MA and Basel, Switzerland.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc didn’t post a salary, so this is our estimate from similar listings.
CMC & Manufacturing, Science and Technology Drug Substance Lead
Sobi
Director, Pharmaceutical Analytical Sciences
Merck & Co., Inc.
CMC & Manufacturing, Science and Technology Drug Substance Lead
Sobi
CMC & Manufacturing, Science and Technology Drug Substance Lead
Sobi
S-IV/Senior Scientist-I
The University of the South Pacific
Small Molecule Drug Substance Lead
GSK plc